2023 World Conference on Lung Cancer (Posters)-EP07.02. Longitudinal ctDNA Testing in Resected, Early Stage Non-small Cell Lung Cancers

Pdf Summary

The study presented at WCLC 2023 focuses on the use of longitudinal ctDNA testing in resected, early-stage non-small cell lung cancers (NSCLC). The researchers aimed to assess the association between ctDNA detection and recurrence-free survival (RFS) in these patients. The study enrolled 70 eligible patients who underwent ctDNA assessment before and after surgery using the RaDaR assay, which can detect up to 48 tumor-specific variants in plasma.<br /><br />The results showed that preoperative ctDNA was detected in 24.6% of patients, while postoperative ctDNA was detected in 1.4% of patients at the 1-month landmark timepoint. Surgical resection led to ctDNA clearance in 94% of cases, except for one patient who had persistent ctDNA at 1 year but remained free of disease radiographically and on targeted therapy. Two patients had recurrences both radiographically and in plasma at 1 year postoperatively.<br /><br />The study also found that patients with higher TNM stage, larger tumor size, squamous histology, PD-L1 expression of 1%, pleural invasion, lymphovascular invasion, and high-grade tumors were more likely to have ctDNA detected.<br /><br />The findings suggest that in patients with early-stage NSCLC, 25% have detectable ctDNA preoperatively, but surgical resection can lead to ctDNA clearance in the majority of cases. The study supports the ongoing testing of ctDNA beyond the initial minimal residual disease assessment in patients with surgically resected disease.<br /><br />The researchers anticipate providing an update with an additional 20 patients with perioperative ctDNA testing and 45 patients with ctDNA results at 1 year post-surgical resection by September 2023. This study highlights the potential of ctDNA testing as a tool for monitoring disease progression and predicting outcomes in early-stage NSCLC patients.

Asset Subtitle

Jamie Feng

Meta Tag

Speaker Jamie Feng

Topic Early-Stage NSCLC: New Technology & Innovations

Keywords

WCLC 2023

ctDNA testing

NSCLC

recurrence-free survival

RaDaR assay

preoperative ctDNA

postoperative ctDNA

surgical resection

disease progression

predicting outcomes